Latest news articles

Added 6 days ago Drug news

Lynparza significantly increased the time without disease progression in women with ovarian cancer

AstraZeneca and MSD’s Lynparza, when added to standard-of-care bevacizumab, significantly increased the time women lived without disease progression. AstraZeneca and...

Added 22 days ago Drug news

NICE recommends Lynparza as first line maintenance therapy for ovarian cancer patients

The National Institute for Health and Care Excellence (NICE) has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer...

Added 1 month ago Drug news

Phase III PRIMA trial of Zejula meets primary endpoint in ovarian cancer

GlaxoSmithKline announced positive results from PRIMA (ENGOT-OV26/GOG-3012), the Phase III randomized, double-blind, placebo-controlled, study of Zejula (niraparib) as a maintenance...

Search all news articles for Cancer of ovary
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Guidelines

Management of epithelial ovarian cancer

This guideline provides recommendations based on current evidence for best practice in screening and the role of prophylactic salpingo-oophorectomy; diagnosis; surgical management; chemotherapy; follow up; management...

Added 5 years ago

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up on non-epithelial ovarian cancer covers diagnosis and pathology/molecular biology, staging and risk assessment, treatment plan...

Added 6 years ago

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up on non-epithelial ovarian cancer covers diagnosis and pathology/molecular biology, staging and risk assessment, treatment plan for early and advanced stages...

Added 7 years ago

Search all guidelines for Cancer of ovary
 

Journal articles

Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.

Recently, Poly-ADP-Ribose Polymerase (PARP) inhibitors are one of the most intensively studied group of antiblastic agents for the management of recurrent ovarian cancer.

Added 1 year ago

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.

Rucaparib is a potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) proteins (PARP-1, PARP-2 and PARP-3) that play an important role in repairing DNA damage and maintaining genomic stability.

Added 1 year ago

Rucaparib: a new treatment option for ovarian cancer.

Areas covered: In this review, the authors discuss the efficacy and toxicity of rucaparib either as a single agent or as a maintenance treatment for ovarian cancer.

Added 1 year ago

Search all journal articles for Cancer of ovary
 

Clinical trials

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer.

Added 29 days ago

PH3 Study of IMGN853 vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced...

Added 2 years ago

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3)

Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib...

Added 6 years ago

Search all clinical trials for Cancer of ovary
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Ovarian cancer: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Cancer of ovary